BC Week In Review | Jul 11, 2016
Clinical News

CHS-131: Phase IIb data

Top-line data from a double-blind Phase IIb trial in 227 treatment-naive patients with RRMS showed that once-daily 3 mg oral CHS-131 met the primary endpoint of reducing the cumulative number of total contrast-enhancing lesions from...
BC Extra | Jun 29, 2016
Clinical News

Coherus' CHS-131 meets Phase IIb MS endpoint

Coherus BioSciences Inc. (NASDAQ:CHRS) said a 3 mg dose of CHS-131 met the primary endpoint of a Phase IIb study to treat relapsing-remitting multiple sclerosis (RRMS). The dose, which was the higher of two in...
BC Extra | Apr 2, 2015
Financial News

Coherus raises $120M in follow-on

Coherus BioSciences Inc. (NASDAQ:CHRS) raised $120 million through the sale of 4.1 million shares at $29 in a follow-on underwritten by JPMorgan; Credit Suisse; and Cowen. Coherus proposed the offering after market Monday, when its...
BC Innovations | Sep 8, 2011
Cover Story

PPARgamma: none is more

A team from Scripps Florida and the Dana-Farber Cancer Institute has developed peroxisome proliferation-activated receptor-g-binding compounds that have potent antidiabetic activity but do not actually agonize the receptor and thus lack the side effects commonly...
BC Innovations | Aug 12, 2010
Cover Story

Resolving the PPARgamma paradox

Researchers at the Dana-Farber Cancer Institute and Scripps Florida have found an alternative mechanism by which peroxisome proliferation-activated receptor-g agonists exert their antidiabetic effects. 1 By blocking phosphorylation of the protein, these compounds actually may...
BC Innovations | Aug 12, 2010
Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Peroxisome proliferation-activated receptor-g (PPARG; PPARg); cyclin dependent kinase 5 (CDK5) In vitro, cell culture and human studies suggest that inhibiting CDK5 phosphorylation of...
BC Week In Review | Oct 5, 2009
Clinical News

INT131: Phase IIb data

The double-blind, U.S. and Mexican Phase IIb INT131-007 trial in 366 Type II diabetics showed that oral INT131 met the primary endpoint of significantly decreasing HbA1c from baseline vs. placebo at 24 weeks (p<0.0001). InteKrin...
BC Extra | Oct 1, 2009
Clinical News

InteKrin's INT131 meets diabetes endpoint

InteKrin Therapeutics Inc. (Los Altos, Calif.) reported that oral INT131 met the primary endpoint of significantly decreasing HbA1c from baseline vs. placebo at 24 weeks in the Phase IIb INT131-007 trial to treat Type II...
BC Week In Review | Mar 16, 2009
Clinical News

INT131: Completed Phase IIb enrollment

InteKrin completed enrollment of 372 patients in a double-blind, placebo-controlled, U.S. and Mexican Phase IIb trial (INT131-007) evaluating 4 dosages of oral INT131 given once daily vs. Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502,...
BC Extra | Aug 5, 2008
Financial News

InteKrin raises $18 million

InteKrin (Los Altos, Calif.) raised $18.3 million in the first closing of a $20 million series C round led by new investor Skyline Ventures. Existing investors Sofinnova Ventures; OrbiMed Advisors; Lanfear Capital; Sears Capital; Vivo;...
Items per page:
1 - 10 of 37